Good News Stories Emerging from the Capital Region Show Solidarity Amid Coronavirus

Published on : Published by : Steven Surdez

Photo Credit: Will Kirk / Johns Hopkins University Good News Stories Emerging from the Capital Region Show Solidarity Amid Coronavirus Endless social media scrolls, 24/7 news channels, newspapers, and radio waves are inundating the public with scary COVID-19 statistics, harrowing tales of medical workers on the front lines of the coronavirus battle, a roller coaster [….]

Coronavirus/COVID-19 Vaccine Insights from Altimmune’s Leadership Team

Published on : Published by : Steven Surdez

Coronavirus/COVID-19 Vaccine Insights from Altimmune’s Leadership Team Coronavirus/COVID-19 continues to radically change daily life across the U.S. Governor Larry Hogan issued an executive order on March 15th ordering the closure of restaurants (take out only), bars, theaters, and fitness centers until further notice from the state. The CDC also changed its guidelines for gatherings from [….]

Altimmune Becomes The Second Maryland-Based Biotech Advance Potential Coronavirus/COVID-19 Vaccine

Published on : Published by : Chris Frew

Altimmune Becomes The Second Maryland-Based Biotech Advance Potential Coronavirus/COVID-19 Vaccine As the coronavirus COVID-19 continues to spread across the U.S.  — there are currently 150 confirmed cases with 11 total deaths as of this writing — several BioHealth Capital Region (BHCR) life science companies are urgently pushing to develop and deploy a COVID-19 vaccine. In [….]

Two Maryland Biotechs Partner to Bring Coronavirus/COVID-19 Vaccine Candidate into Clinical Trials

Published on : Published by : Steven Surdez

Two Maryland Biotechs Partner to Bring Coronavirus/COVID-19 Vaccine Candidate into Clinical Trials Emergent BioSolutions and Novavax, both headquartered in the BioHealth Capital Region, announced today a partnership to bring Novavax’s potential COVID-19 vaccine to the clinic. The companies have structured their collaboration anticipating the start of Phase I clinical vaccine trials to start in the [….]